Imatinib mesylate pharmacokinetics

Erye RE, Eitzgerald SM, Lagattuta TF, Hruska MW, Egorin MI. Effect of St John s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Therapeut 2004 76(4) 323-329. 

O Brien SG et al (2003) Effects of imatinib mesylate (STI571, glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89 1855-1859... 

Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrpl (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec) implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005 65 2577-2582. 

Smith P. The influence of St John s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004 24 1508-1514. 

Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects, Cancer ChemotherPharmacol 2004) 53,102-6. 

Extraction recovery >90%. The method can be routinely used in pharmacokinetic and drug interaction studies. An LC-MS-MS method used in a pharmacokinetic study where imatinib mesylate (Glivec) and its main metabohte (CGP74588) were measured in blood samples of a patient with end-stage renal disease on hemodialysis and compared with... 

Pappas, R, Karavasilis, V., Briasoulis, E., Pavlidis, N. and Marselos, M., Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother. Pharmacol., 65(4), 358-360 (2005). 

---